However, in a few cases, HPV vaccination has been shown to be a good treatment alternative for patients with recalcitrant skin warts. Here we report five cases of recalcitrant genital warts that responded well to treatment with the nonavalent HPV vaccine. HPV vaccines could be beneficial as ...
620 Minerva GinecoloGica october 2016© 2016 eDiZioni Minerva MeDicaThe online version of this article is located at http://www.minervamedica.itMinerva Ginecologica 2016 october;68(5):620-1nonavalent HPv vaccine (HPv-9): analysis of pre-registration dataDear editor,Human papillomavirus (HPv) ...
a novel vaccine (i.e., originating from the presence of single HPv genotypes) may guar-antee a higher and longer antibody level, expanding the primary prevention perspective also to some non-16/18 genotypes. This is the rationale of nonavalent HPv vac-cine (HPv-9), which includes, in ...
The nonavalent HPV vaccine has the potential to accelerate the elimination of cervical cancer. The 90-70-90 strategy is a global target set by the World Health Organization (WHO) to achieve the elimination of cervical cancer by 2030. This target includes three main indicators: 90% of all ...
Human Papillomavirus (HPV) infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HP...
A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are ...
Human Papillomavirus (HPV) infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HP...
In the context of the arrival of a nonavalent HPV vaccine (6/11/16/18/31/33/45/52/58), this analysis aims to estimate the public health impact and the incremental cost-effectiveness of a universal (girls and boys) vaccination ... KH Jalil,R Acevedo,V Daniels,... - 《Value in Healt...
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina, anus, penis, oropharynx as well as the causal factor in other diseases suc... F Mennini,...
Potential cost- effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014;134(9):2264-8. Publication en ligne du 31 oct... Franco,L E.,Brisson,... - 《Journal International Du Cancer》 被引量: 54发表: 2014年 Impact and Cost-effectiveness of 3 Doses of 9-...